Xieteng Medical: Uncovering the 'Silent Killer' in the Human Body – A Full-Chain VTE Prevention and Treatment Solution Provider
Thrombus: The Most “Silent” Killer in the Human BodyIt is termed “silent” because its onset is insidious and its clinical symptoms are highly atypical, making it prone to misdiagnosis and missed diagnosis. It is defined as a “killer” because when a thrombus reaches a certain size, it can dislodge and occlude blood vessels, causing comprehensive failure of the circulatory system and ultimately leading to the loss of vital signs.
VTE, or venous thromboembolism, is the third most common vascular disease after ischemic heart disease and stroke.Venous thromboembolism (VTE) comprises two main forms: pulmonary thromboembolism (PTE) and deep vein thrombosis (DVT). It has a high incidence among hospitalized patients and is one of the significant causes of in-hospital unexpected deaths and perioperative mortality. In recent years, it has attracted considerable attention from relevant national authorities, hospital administrators, and clinical healthcare professionals.
The key to solving the problem lies in prevention. Especially in clinical medicine, prevention is the most cost-effective and effective health strategy. Although VTE has a powerful "hidden function," it is not without its "cracking method." Targeted preventive measures can still reduce its threat, so that thrombosis no longer "blocks" patients.
The immense market demand has opened up breakthroughs for innovation, attracting numerous innovative companies to enter the field of thrombosis prevention and treatment, with Xieteng Medical standing out as a leading player.
In 2019, Zhai Zhenguo, academic leader of the Pulmonary Embolism and Pulmonary Vascular Disease Group at the Respiratory Center of China-Japan Friendship Hospital, published findings in the international journal *Chest* from a multicenter study investigating VTE risk characteristics and prophylaxis among medical and surgical inpatients across more than 60 hospitals in China.Among surgical inpatients, 86.1% were at moderate-to-high risk for venous thromboembolism (VTE), while 63.4% of medical inpatients were at high risk for VTE. However, only 14.3% of these patients received VTE prophylaxis, and merely 10.3% received appropriate prophylactic measures.
Why Is There Such a Wide Disparity in VTE Prevention Despite the High Incidence Rate?
The development of any phenomenon is a gradual process. In the realm of thrombosis prevention and treatment, due to a lack of attention in the early stages, many people remain largely unfamiliar with thrombosis and have not prioritized it. However, as fatal thrombotic events have become increasingly frequent, coupled with the successive introduction of supportive policies, public attention has gradually shifted to this field, prompting the targeted adoption of appropriate preventive measures.
However, the current situation is far from ideal, primarily due to the following three reasons:First, from the perspective of hospitals, compared with early prevention, hospitals focus more on the clinical treatment phase. Consequently, they place insufficient emphasis on thrombosis prevention, often addressing it only superficially or merely to comply with routine inspections. Second, from the perspective of physicians, due to the lack of a unified regulatory platform, doctors tend to rely on chance during diagnosis and treatment, demonstrating low initiative and autonomy. Third, from the perspective of enterprises, owing to their limited social influence, there is a severe shortage of both capital investment and qualified talent. Thrombosis prevention and treatment products currently available on the market primarily offer basic functionalities and have not yet evolved into systematic solutions.
Potential issues have gradually become clear, and experts have accordingly proposed detailed solutions. Meanwhile, the government is also making concurrent efforts by introducing a series of policy measures for VTE prevention, explicitly stating its intention to leverage the medical consortium model and focus on healthcare quality and patient safety to drive the entire field of thrombosis prevention and treatment into a phase of rapid development.
However, after extensive market research, Jin Linxin, founder of Xieteng Medical, discovered that despite policy support and available solutions, few were willing to enter this field. Yet Jin, with his background in medical engineering, held a distinctly different view: he established Xieteng Medical in 2016, becoming one of the earliest entrepreneurs in this sector.
When discussing entrepreneurship, Jin Linxin is resolute. “Throughout my many years in the medical field, I have been searching for a core value to drive my professional growth. That value now defines Xieteng Medical’s mission: to address customer needs with dedication and make tangible contributions to society. Observing that few players had entered the field of venous thromboembolism (VTE) prevention, I asked myself whether I could step in to fill this gap in the ecosystem, meet the practical needs of healthcare professionals, and thereby create greater value for the entire medical industry.”
Corporate development often requires continuous optimization of one’s products. For Xieteng Medical, product development is more akin to an “evolutionary history” marked by the ongoing identification and resolution of issues.
In the first phase, Xieteng Medical set its sights on thrombosis prevention devices., it has developed core products such as intermittent pneumatic compression devices, plantar venous pumps, and compression stockings; however, sales volumes remained low after these products entered the market.
The direct setbacks did not crush Jin Linxin’s momentum to move forward. He quickly identified the root cause of the problem: “When promoting our products to customers, we found that the vast majority of them had a very limited clinical understanding of the entire field of thrombosis prevention and treatment. This led to low customer awareness of our products; consequently, despite the product’s high quality, it still lacked market traction. After encountering these obstacles, we promptly devised a solution, namely”Advanced Stage II – Medical Education。”
Offline Training Event
By conducting thematic seminars, offline training sessions, and collaborating with medical associations to establish a quality control system for thrombosis prevention and treatment, we aim to build a standardized and systematic knowledge framework for our user base. Additionally, by developing informational products and defining operational procedures, we comprehensively enhance users’ mastery of thrombosis prevention and control, thereby maximizing the application value of our devices.
Yet problems kept arising one after another. Through continuous exploration, Jin Linxin discovered that, in addition to healthcare professionals’ lack of clinical knowledge, the hospital lacked a comprehensive operational system. However, VTE management inherently involves multiple departments and requires interdepartmental collaboration. Based on this, Xieteng Medical embarked onThe third stage of development involves establishing a comprehensive, end-to-end thrombosis prevention and control management system for hospitals.
Full-Process Thrombosis Prevention and Control Management System
This system constructs a thrombosis prevention and control framework driven by dual engines of medical big data and medical knowledge, leveraging professional multi-dimensional medical data analysis techniques and expertise in quality control data mining. The system specifically serves three user interfaces: the physician interface enables score entry, VTE moderate-to-high risk alerts, and disease-specific patient follow-up management; the nursing interface allows qualitative selection based on the hospital’s SOPs (Standard Operating Procedures) using the Caprini and Padua scoring templates provided by the system; and the quality control interface, serving as the monitoring portal for the Medical Affairs Department, is responsible for real-time hospital-wide scoring, monitoring of moderate-to-high risk critical values, comprehensive real-time surveillance, indicator monitoring, departmental monitoring, and advanced database search functions.
After resolving the issues on the healthcare provider and hospital sides, Jin Linxin faced a new challenge: patients also required relevant knowledge training. In response to this, Xieteng Medical enteredThe Fourth Stage of Development: Providing Services to Patients, and thereby developed the “Quanmin Yijianbao” Internet-based VTE Patient-Provider Education System.
“Quanmin Yijianbao” establishes an online communication channel for healthcare professionals and patients. Patients can access customized medical health education videos related to their own care, as well as hospital-specific content they need to understand, via the app. They can also enjoy health services provided by hospitals and the “Quanmin Yijianbao” team. Meanwhile, healthcare professionals can effectively manage patients’ hospitalization information and monitor their progress in viewing health education videos in real time through the app, thereby creating a two-way interaction.
Building on this foundation, Jin Linxin identified a new point of integration by incorporating rehabilitation concepts into the learning process, encouraging patients to get out of bed and engage in appropriate physical activity. This approach not only effectively prevents thrombosis but also promotes rapid postoperative recovery.
Adopting a problem-oriented approach, Xieteng Medical has developed tailored solutions for each stage of its development, ultimately establishing an integrated thrombosis prevention and management solution that encompasses training, prevention, management, and implementation. Supported by information technology, the company is driving its products toward greater efficiency, higher quality, and elevated standards, thereby delivering enhanced value to healthcare professionals and patients.
Xieteng Medical’s systematic product portfolio has also enabled the company to establish large-scale market channels. Jin Linxin told VCBeat, “For Xieteng Medical, we are no longer selling individual products; instead, we are marketing our comprehensive operational programs. From source to final implementation, these programs are supported by a complete operational framework, including healthcare professional training and hospital-wide information management. With detailed plans for each step, end users can simply implement the program in phases and steps according to the established roadmap.”
Driven by its products, Xieteng Medical has achieved tremendous success in the market,To date, cooperation agreements have been signed with nearly 70 hospitals in Zhejiang Province, receiving positive feedback from users.
But this is not the end for Xieteng Medical; Jin Linxin has more detailed plans for the future.
First, strengthen "industry-academia-research" collaboration to refine products with precision.Products remain the core embodiment of a company’s competitive advantage. Therefore, Xieteng Medical will fully leverage its “industry-academia-research” collaborative strengths, continuously break through technical barriers, and refine its product offerings for different departments and application scenarios on the basis of integrated services, thereby establishing a sustainable competitive edge.
Second, leveraging Zhejiang Province as a successful case study to replicate and promote the model across the national market.Currently, Xieteng Medical’s market presence is entirely concentrated within Zhejiang Province. This strategy serves two purposes: first, to rapidly refine its products; and second, to establish a standardized operational system with a regional focus. With the support of capital, the company aims to quickly expand its market coverage across China through “model replication.”
Third, it has achieved scale, with annual sales surpassing the 100 million yuan mark.In 2020, Xieteng Medical’s annual sales reached the tens of millions of yuan level. However, in Jin Linxin’s view, there remains significant room for future growth. With the continuous improvement of its product portfolio and the gradual optimization of market channels, Xieteng Medical’s annual sales are expected to surpass the 100 million yuan mark in 2021.
Fourth, strengthen publicity and leverage the power of the media to raise awareness of thrombosis prevention and treatment.The field of thrombosis prevention and treatment started relatively late, and currently still faces the social issue of low market penetration. Therefore, for Xieteng Medical, which focuses on this area, in addition to exerting efforts on product development and market layout, it is also necessary to put significant effort into promotion. Jin Linxin hopes to leverage the power of media to quickly bring thrombosis prevention and treatment into public view, thereby enabling more people to understand thrombosis prevention and treatment, and attracting more like-minded individuals to join the front lines of thrombosis prevention and treatment.
Thrombosis is a “ticking time bomb” lurking between patients and hospitals, posing a risk of detonation at any moment if even slight carelessness occurs. Therefore, for Xieteng Medical, this represents an extremely formidable challenge, as well as a significant market opportunity.
The path forward is always fraught with challenges, but Xieteng Medical remains undaunted. Instead, it is committed to solving user problems as its core mission, continuously optimizing its products to deliver greater value.